SARS-CoV-2

[iScience] Investigators demonstrated that silencing the circadian regulator Bmal1 or treating lung epithelial cells with the REV-ERB agonist SR9009 reduced ACE2 expression and inhibited SARS-CoV-2 entry and replication.

[Biochemical and Biophysical Research Communications] A549 cells in air-liquid interface culture yielded a layer of mucus on their apical surface, exhibited decreased expression levels of the proliferation marker KI-67 and intriguingly became susceptible to SARS-CoV-2 infection.

[Blood Cancer Discovery] Scientists analyzed anti-SARS-CoV-2 spike IgG antibody titers and neutralizing Ab among 217 recipients of cellular treatments, such as allogeneic and autologous hematopoietic cell transplant and chimeric antigen receptor T cell therapy.

[Quanterix Corporation] Quanterix Corporation announced that the FDA has expanded the Emergency Use Authorization label for its Simoa® SARS-CoV-2 N Protein Antigen Test to include testing with nasal swab and saliva samples, and for asymptomatic serial testing with nasal swab samples.

[Cell] The authors showed that a clinical stage multivalent SARS-CoV-2 spike receptor-binding domain nanoparticle vaccine protected mice from SARS-CoV-2 challenge after a single immunization, indicating a potential dose-sparing strategy.

[Science Translational Medicine] Researchers isolated 216 monoclonal antibodies targeting SARS-CoV-2 from plasmablasts and memory B cells collected from patients with coronavirus disease 2019.